MedTrace Logo

Safety and Tolerability of CDX-6114 in Healthy Volunteers

NCT03577886 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2018-09-20

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and tolerability of an oral solution of CDX-6114 when administered as a single dose in healthy volunteers.

Conditions

  • Healthy

Interventions

DRUG

CDX-6114

CDX-6114 will be administered as a single, oral dose solution at dose levels of 0.225, 0.75, 2.25, and 7.5 g.

DRUG

Placebo

Phosphate Buffer Diluent oral solution

Sponsors & Collaborators

  • Codexis Inc.

    lead INDUSTRY

Principal Investigators

  • Sam Salman · Linear Clinical Services

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-07-04
Primary Completion
2018-08-21
Completion
2018-09-04

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03577886 on ClinicalTrials.gov